Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZK-807834. Berlex.

Uma Sinha1

  • 1Millennium Pharmaceuticals Inc, 256 East Grand Avenue, South San Francisco, CA 94080, USA. uma.sinha@mpi.com

Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

JACC. CardioOncology·2026
Same author

Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.

Journal of cardiac failure·2026
Same author

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

JAMA cardiology·2026
Same author

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

Future cardiology·2025
Same author

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

JAMA cardiology·2025

Berlex and Pfizer are developing ZK-807834 (CI-1031), a novel Factor Xa inhibitor, for treating unstable angina pectoris. This parenteral medication shows potential for managing this serious cardiovascular condition.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Unstable angina pectoris is a critical manifestation of coronary artery disease.
  • Current treatments for unstable angina have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To introduce ZK-807834 (CI-1031), a Factor Xa inhibitor, as a potential parenteral therapy for unstable angina pectoris.

Main Methods:

  • Development of ZK-807834 (CI-1031) by Berlex and Pfizer.
  • Focus on Factor Xa inhibition mechanism.
  • Exploration of parenteral administration routes.

Main Results:

  • ZK-807834 (CI-1031) is identified as a promising Factor Xa inhibitor.

Related Experiment Videos

  • Potential for effective parenteral treatment of unstable angina pectoris.

    • Conclusions:

    • ZK-807834 (CI-1031) represents a novel therapeutic candidate for unstable angina.
    • Further development is warranted to establish its efficacy and safety in patients.